文献速递前列腺癌

化疗初治转移性去势抵抗性前列腺癌的一线非细胞毒性治疗:10项随机临床试验的系统综述

First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials.
PubMed 文献 · BJU Int · 2017-02-28

该系统综述检索至2016年3月1日的PubMed、EMBASE和Cochrane图书馆,纳入10项随机临床试验的25篇文章,评估化疗初治转移性去势抵抗性前列腺癌(mCRPC)的一线非细胞毒性治疗。最佳证据支持阿比特龙联合泼尼松和恩扎卢胺可有效延长总生存期(OS)和无进展生存期(PFS),但考虑生活质量和不良事件时,其他治疗模式可考虑用于个体患者。

要点

  • 阿比特龙联合泼尼松对比安慰剂联合泼尼松,延长OS和PFS的证据质量高。
  • 恩扎卢胺对比安慰剂延长OS和PFS的证据质量高;对比比卡鲁胺延长PFS的证据质量高,但对OS影响未知。
  • 镭-223、sipuleucel-T和比卡鲁胺对比安慰剂均延长OS(证据质量高至中等),但PFS获益情况未知或未延长。

核心结论

  • 阿比特龙和恩扎卢胺延长化疗初治mCRPC患者OS和PFS的证据最佳。
  • 考虑生活质量和不良事件时,其他治疗模式可考虑用于个体患者。

研究设计与样本

  • 系统检索PubMed、EMBASE和Cochrane图书馆截至2016年3月1日的同行评议随机临床试验(RCT)文献。
  • 纳入25篇文章,报告10项独特RCT,描述7种不同比较。
  • 采用Cochrane协作组工具评估偏倚风险,采用GRADE工作组方法对证据分级。

主要发现

  • 在一项RCT中,阿比特龙联合泼尼松对比安慰剂联合泼尼松延长OS和PFS(高质量证据)。
  • 在一项RCT中,恩扎卢胺对比安慰剂延长OS和PFS(高质量证据)。
  • 在两项RCT中,镭-223对比安慰剂延长OS(高质量和中等质量证据),但对PFS的影响未知。
  • 在三项RCT中,sipuleucel-T对比安慰剂延长OS(中等质量证据),但未延长PFS(低质量证据)。
  • 在一项RCT中,orteronel对比安慰剂延长PFS(高质量证据),但未延长OS(中等质量证据)。

关键数值与推荐

  • 在一项RCT中,比卡鲁胺对比安慰剂延长OS(中等质量证据),但对PFS的影响未知。
  • 在一项RCT中,恩扎卢胺对比比卡鲁胺延长PFS(高质量证据),但对OS的影响未知。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this study is to systematically evaluate all available treatment options in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC). We systematically searched PubMed, EMBASE, and the Cochrane libraries up to 1 March 2016 for peer-reviewed publications on randomised clinical trials (RCTs). RCTs were included if progression-free survival (PFS), overall survival (OS), quality of life (QoL), or adverse events (AEs) were quantitatively evaluated. We assessed the risk of bias with the Cochrane Collaboration's tool and graded the evidence with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group's approach. We included 25 articles, reporting on 10 unique RCTs describing seven different comparisons. In one RCT, a prolonged OS and PFS (high quality) were found with abiraterone and prednisone compared to placebo plus prednisone. In one RCT, a prolonged OS and PFS (high quality) were found with enzalutamide compared to placebo. In two RCTs, a prolonged OS (high and moderate quality) was found with 223 radium compared to placebo, but its effect on PFS is unknown. In three RCTs, a prolonged OS (moderate quality) was found with sipuleucel-T compared to placebo, but no prolonged PFS (low quality). In one RCT a prolonged PFS (high quality) was found with orteronel compared to placebo, but no prolonged OS (moderate quality). In one RCT, a prolonged OS (moderate quality) was found with bicalutamide compared to placebo, but its effect on PFS is unknown. In one RCT, a prolonged PFS (high quality) was found with enzalutamide compared to bicalutamide, but its effect on OS is unknown. The best evidence was found for abiraterone and enzalutamide for effective prolongation of OS and PFS to treat chemotherapy-naive patients with mCRPC. However, taking both QoL and AEs into consideration, other treatment modalities could be considered for individual patients.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Poorthuis MHF, Vernooij RWM, van Moorselaar RJA, et al. First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials. BJU Int. 2017. PMID: 28063195. doi:10.1111/bju.13764

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。